Alluvi, known as BI 4744, offers a significant development in obesity therapy. This dual agonist targeting both glucagon-like peptide-1 and GIP targets demonstrates impressive efficacy in patient trials, arguably outperforming existing GLP-1 site agonists. Early data suggest substantial {weight d